Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:1020 (3 May), doi:10.1136/bmj.39564.454502.C2
Rudiger Pittrof, consultant in integrated sexual health and HIV1, Ian Rubenstein, general practitioner2
1 Department of Reproductive and Sexual Health Care, Town Clinic, Enfield, Middlesex, 2 Eagle House Surgery, Ponders End, Enfield
Correspondence to: R Pittrof rudiger.pittrof@enfield.nhs.uk
| The first 150 words of the full text of this article appear below. |
Discussion of the planned use on patients of the placebo effect is long overdue. For many years it has been medicines "dirty little secret." Clinicians have found it to be an embarrassment that needs to be factored in when planning randomised controlled trials. Ethically its use has always been considered dubious. Recent high profile publications suggesting the lack of efficacy of selective serotonin reuptake inhibitors (SSRIs) in mild to moderate depressive illness have shown that clinicians routinely make use of the placebo effect—but from a position of ignorance rather than intention.1
Whatever ones ethical stance, this state of affairs cannot be a good thing for our patients, our relationship with our patients, or the public purse. We outline a third way whereby clinicians can use the placebo knowingly yet still stay within the ethical constraints of modern medical practice.
Drugs given to conscious patients have at least three effects: one
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+